SAG Unveils LiquidMate O: A Breakthrough UHF RFID Tagging Solution for Item-Level Traceability of Liquid-Filled Injectable Medications

Patent-pending direct-on-vial RFID label enables DSCSA-ready traceability across pharmaceutical manufacturing and hospital workflows

TAICHUNG, Jan. 20, 2026 /PRNewswire/ -- SAG today announced LiquidMate O, its debut UHF RFID label and a category-defining advancement in pharmaceutical RFID and item-level traceability. Built on an innovative, patent-pending antenna architecture, LiquidMate O delivers reliable direct-on-vial RFID tagging for liquid-filled injectable medications, an application long considered one of the most technically challenging in RFID deployment. Ineffective tracking of injectable drugs continues to drive substantial losses through expired inventory, misplaced medications, and regulatory exposure—particularly for high-value or critical products. As enforcement of the U.S. Drug Supply Chain Security Act (DSCSA) accelerates, dependable, high-accuracy RFID-based medication tracking has become essential to both pharmaceutical manufacturing and hospital operations.

LiquidMate O is purpose-built to enable scalable, item-level tracking across a broad range of injectable liquid categories that have historically constrained direct-on-vial RFID adoption. Its performance has been independently validated through AXIA Lab–defined test scenarios, using representative liquid formulations and workflow conditions aligned with real clinical practice. Key capabilities include:

• One label across multiple formulations
  Consistent RFID performance across injectable liquids with varying dielectric properties, eliminating formulation-specific labels and significantly reducing SKU complexity.
• True direct-on-vial design
  Validated on industry-standard 10 mL glass vials with a compact 62 × 20 mm label engineered for curved, space-constrained pharmaceutical packaging.
• Proven high-density readability
  Independently validated by AXIA Lab, achieving 100% read performance in dense, multi-vial configurations with full 360-degree omnidirectional readability.

While demand for item-level traceability continues to rise, existing RFID approaches have struggled to balance RF performance, scalability, and operational integration. Conventional direct-on-vial solutions often suffer from inconsistent performance on liquid-filled injectables due to dielectric effects, while flag-style labels, although RF-robust, pose handling, automation, and scalability challenges that limit broader adoption. LiquidMate O eliminates this trade-off by delivering a true direct-on-vial RFID solution with consistent performance across diverse injectable formulations. This enables streamlined labeling operations and improved workflow efficiency from manufacturing through point-of-care. By reducing manual scanning steps and minimizing SKU proliferation, LiquidMate O supports real-time inventory visibility, accurate dispensing, and enhanced patient safety without disrupting existing packaging lines.

"With more than two decades of experience supporting healthcare and industrial RFID applications, we have seen how reliability at the item level directly impacts compliance, efficiency, and patient safety," said Terry Chiang, CEO of SAG. "LiquidMate O reflects our focus on solving the most technically complex tagging challenges in healthcare and delivering scalable, standards-based traceability solutions that pharmaceutical organizations can deploy with confidence."

Following extensive engineering development and independent validation, LiquidMate O is now qualified for commercial deployment. Built on SAG's deep expertise in RFID antenna design, materials science, and healthcare workflow integration, the solution is engineered to meet the stringent performance, regulatory, and scalability requirements of pharmaceutical environments. SAG is initiating structured technical engagements to support evaluation and deployment planning for next-generation item-level traceability initiatives.

About SAG

As an RFID tagging challenge enabler, SAG turns complex concepts into production-ready RFID solutions. Through deep expertise in tailored antenna design, materials science, and self-developed manufacturing systems, SAG delivers reliable RFID connectivity that performs under demanding operational and environmental constraints—enabling organizations to address complex, mission-critical workflow challenges through advanced RFID solutions.

www.sag-rfid.com
info@sag.com.tw 

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

SAG Unveils LiquidMate O: A Breakthrough UHF RFID Tagging Solution for Item-Level Traceability of Liquid-Filled Injectable Medications

Funding will scale hospital deployments for groundbreaking CT:VQ™ imaging product, strongly advance R&D, support early adopters at Stanford, Cleveland Clinic, University of Miami, UC San Diego Health, and more

LOS ANGELES and MELBOURNE, Australia, Jan. 20, 2026 /PRNewswire/ -- 4DMedical, the leader in software-based respiratory imaging technology, today announced US$100+ million (AU$150 million) in new institutional placement. The investment will primarily be leveraged to accelerate U.S. adoption of its class-leading "CT:VQ™" product and significantly boost research and development—bolstering 4D's technology lead in software-based lung imaging.

CT:VQ™ is 4DMedical's FDA-cleared, SaaS technology that provides ventilation and perfusion insights from CT imaging. Within just four months of FDA clearance, CT:VQ was deployed by four elite U.S. academic medical centers: Stanford, Cleveland Clinic, University of Miami, and UC San Diego Health. These rapid adoptions reflect growing interest from clinicians seeking quantified, actionable and functional information not available from traditional imaging--but increasingly vital to support diagnosis, treatment planning, and longitudinal monitoring.

"This is an extraordinarily important and validating event for multiple reasons," says Andreas Fouras, PhD, 4DMedical Founder and CEO. "First, it reflects growing global recognition of the technological leadership of 4DMedical, including our groundbreaking products such as CT:VQ™. And it recognizes both the commercial progress and even greater growth potential we have in the U.S. With this strong institutional backing and a strengthened balance sheet, we will scale adoption, accelerate R&D, deepen partnerships, and dominate the global marketplace for software-based lung imaging tools."

What the funding enables for hospitals and health systems

4DMedical will use the funding to expand U.S. availability of CT:VQ™ and support health systems with implementation at scale, including:

• Commercial expansion across U.S. academic medical centers and health systems, with a focus on real-world adoption and multidisciplinary use
• Customer success, training, and technical support to help integrate CT:VQ™ into existing clinical workflows and drive consistent utilization
• Ongoing research and development to expand 4DMedical's technology leadership, product portfolio and capabilities in functional lung imaging
• Operational scale and flexibility to support additional growth opportunities and sustained clinical partnerships

Following the raise, 4DMedical reported a pro forma cash position exceeding US$130+ million (AU$200+ million), which will support the company's U.S. expansion strategy and growing installed base.

Built to integrate into clinical workflows

4DMedical's products are delivered through a Software-as-a-Service (SaaS) model designed to integrate with existing hospital infrastructure. The company also highlighted strategic partnerships, including with Philips, aimed at supporting broader adoption pathways.

Availability

Hospitals and imaging networks interested in evaluating CT:VQ™ can contact 4DMedical for implementation information, workflow considerations, and a demonstration.

About 4DMedical

4DMedical Limited (ASX:4DX) is a global medical technology company that creates and deploys the most advanced software-based cardiothoracic imaging technology—integrating both proprietary algorithms and artificial intelligence. 4DMedical's software platform delivers deep, quantitative, insights from routine clinical imaging to help clinicians assess lung function and cardiopulmonary disease with significantly greater precision.

These insights help pulmonologists, radiologists and hospital teams quantify regional lung function, support diagnosis and disease monitoring, and inform treatment and surgical planning. 4DMedical's solutions are designed to integrate into existing clinical workflows. They provide actionable, patient-specific information that supports better decision-making and operational efficiency across a range of respiratory conditions. Learn more at www.4dmedical.com.

Photo - https://mma.prnasia.com/media2/2865006/4DMedical_Respiratory_Imaging.jpg?p=medium600

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

4DMedical Secures US$100+ Million Funding to Accelerate U.S. Expansion and increase Technology Dominance in Software-Based Lung Imaging